Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 4/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.45 |
| ▸ | MMP2 | P08253 | 9/20 | 0.44 |
| ▸ | MMP1 | P03956 | 4/20 | 0.44 |
| ▸ | MMP3 | P08254 | 4/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7610347 | 0.89 | L3MBTL1 (0.49) | PSMB5HDAC3HDAC4HDAC1HDAC2 | |
| SCHEMBL7612584 | 0.85 | HDAC3 (0.51) | HDAC3HDAC4HDAC1HDAC2HDAC8 | |
| SCHEMBL3701701 | 0.83 | PSMB5 (0.50) | PSMB5TP53HDAC3HDAC4HDAC1 | |
| SCHEMBL7617954 | 0.83 | PSMB5 (0.50) | PSMB5TP53HDAC3HDAC4HDAC1 | |
| SCHEMBL7620286 | 0.83 | CYP1A2 (0.44) | — | |
| SCHEMBL7614816 | 0.82 | ACE (0.53) | PSMB5HDAC3HDAC4HDAC1HDAC2 | |
| SCHEMBL5020125 | 0.81 | PSMB5 (0.55) | PSMB5TP53HDAC3HDAC4HDAC1 | |
| SCHEMBL9487298 | 0.80 | TP53 (0.61) | PSMB5TP53 | |
| SCHEMBL9487303 | 0.80 | TP53 (0.61) | PSMB5TP53 | |
| SCHEMBL5020128 | 0.78 | HDAC3 (0.51) | HDAC3HDAC4HDAC1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122792-A1 | S-t-BUTYL PROTECTED CYSTEINE DI-PEPTIDE ANALOGS AND RELATED COMPOUNDS | PROMENTIS PHARMACEUTICALS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122792-A1 | S-t-BUTYL PROTECTED CYSTEINE DI-PEPTIDE ANALOGS AND RELATED COMPOUNDS | CSTB, IAPP, VIP | PSMB5 1294/4885TP53 511/4885BIRC2 531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.